Determination of prevalence of depression in an epilepsy clinic using a brief DSM-IV-based self-report questionnaire

Seminario, Nicole A.; Farias, Sarah E Tomaszewski; Jorgensen, Julie; Bourgeois, James A.; Seyal, Masud

doi:10.1016/j.yebeh.2009.05.007

Cited by 42 publications

(27 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has good psychometric properties, a sensitivity of 88, and specificity of 88% for current major depression (Kroenke et al., 2001), and can be administered over the telephone (Pinto‐Meza et al., 2005). The PHQ‐9 has been used to classify individuals according to current major depression (and subthreshold depression) in general population settings (Martin et al., 2006) as well as in specific neurologic populations including epilepsy (Haut et al., 2009; Seminario et al., 2009), traumatic brain injury (Fann et al., 2005), and stroke (Williams et al., 2005).…”

Section: Methodsmentioning

confidence: 99%

Evaluation of depression risk in LGI1 mutation carriers

et al. 2010

View full text Add to dashboard Cite

SUMMARYPurpose: Depression is the most common comorbid condition in epilepsy. The cause of this comorbidity is unknown, and could involve psychosocial consequences of epilepsy, treatment side effects, seizure manifestations, or common neurobiologic mechanisms. One hypothesis of particular interest is a shared genetic susceptibility to epilepsy and depression. We tested this hypothesis by studying depressive symptoms in families with an identified genetic form of epilepsy: autosomal dominant partial epilepsy with auditory features caused by mutations in the leucine-rich, glioma inactivated 1 gene (LGI1). Methods: A standardized depression screen was administered to 94 individuals from 11 families with mutations in LGI1, including 38 mutation carriers with epilepsy (AC), 11 clinically unaffected mutation carriers (UC), and 45 noncarriers (NC). Results: Current depressive symptom scores were significantly higher in AC than in NC, an association that remained after excluding depressive symptoms that appeared likely to be caused by antiepileptic medication use. However, scores did not differ between UC and NC. Discussion: Although LGI1 mutation carriers who were clinically affected with epilepsy had increased depressive symptoms, mutation carriers without epilepsy did not. These findings suggest that the increase in depressive symptoms in affected individuals from these families is related to epilepsy or its treatment rather than to LGI1 mutations per se.

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of depression risk in LGI1 mutation carriers

et al. 2010

View full text Add to dashboard Cite

show abstract

“…as a “gold-standard” diagnostic reference (21) . Few other studies evaluated PHQ-9 in patients with epilepsy, including two papers that focused on psychometrics (22–27) . This supports the notion that PHQ-9 can and indeed has been used to screen for depression in epilepsy.…”

Section: Introductionmentioning

confidence: 99%

Validation of the Patient Health Questionnaire-9 (PHQ-9) for depression screening in adults with epilepsy

Rathore

Jehi

Fan

et al. 2014

Epilepsy & Behavior

View full text Add to dashboard Cite

Objective Assess accuracy and operating characteristics of the Patient Health Questionnaire-9 (PHQ-9) for depression-screening in adults with epilepsy. Methods Tertiary epilepsy center patients served as the study population with 237 agreeing to structured interview using the Mini-International Neuropsychiatric Interview (MINI), a “gold standard” instrument developed for rapid diagnosis of neuropsychiatric disorders, including major depressive disorder (MDD); 172 also completed the PHQ-9, and 127 completed both the PHQ-9 and the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) within two days of the MINI. Sensitivity, specificity, positive & negative predictive values & areas under the ROC curves for each instrument were determined. Cut-points of 10 for the PHQ-9 and 15 for the NDDI-E were used and ratings at or above the cut-points were considered screen-positive. The PHQ-9 was divided into cognitive/affective (PHQ-9/CA) and somatic (PHQ-9/S) subscales to determine comparative depression-screening accuracy. Results The calculated areas under the ROC curves for the PHQ-9 (n=172) and the PHQ-9/CA and PHQ-9/S sub-scales were 0.914, 0.924, and 0.846, respectively, with the PHQ-9 more accurate than the PHQ-9/S (p=0.002) but no different than the PHQ-9/CA (p=0.378). At cut-points of 10 and 15, respectively, the PHQ-9 had higher sensitivity (0.92 vs 0.87), but lower specificity (0.74 vs 0.89) than the NDDI-E. The areas under the ROC curves of the PHQ-9 and the NDDI-E showed similar accuracy (n=127; 0.930 vs 0.934; p=0.864). Significance The PHQ-9 is an efficient & non-proprietary depression screening instrument with excellent accuracy validated for use in adult epilepsy patients as well as multiple other medical populations.

show abstract

“…[1] Most of the time it is underrecognized and has a huge impact on their quality of life. [1–3] Patients with epilepsy have a higher prevalence of depression than the general population and studies estimate the incidence to range between 20 and 54%. [4–6]…”

Section: Introductionmentioning

confidence: 99%

Depression in patients with epilepsy: A study from Enugu, South East Nigeria

Onwuekwe

Bzeala-Adikaibe

et al. 2012

Ann Med Health Sci Res

View full text Add to dashboard Cite

Background:Depression is a common psychiatric disorder in epilepsy patients. A bidirectional interaction is thought to be present between epilepsy and depression. There are few studies of this relationship in Nigerian Africans.Objectives:This was a cross-sectional study of the frequency and pattern of depression in a cohort of epilepsy patients in Enugu, South East Nigeria.Materials and Methods:Adult patients with epilepsy seen at the University of Nigeria Teaching Hospital, Enugu, from May to September 2009 were assessed for depression using the Becks Inventory for Depression. Informed consent was obtained from each patient. Clinical data obtained were analyzed using Statistical Package for the Social Sciences, version 15. The hospital's ethical review committee approved the study.Results:I0 n all, 83 subjects were studied (50 males and 33 females). They were aged from 18 to 75 years, with an average of 29.87 years. Most subjects were <25 years of age, single (53, 64%) and had at least secondary school education (65, 78%). Depression was present in 71 (85.5%) subjects – minimal 57 (68.7%), mild 10 (12%), and moderate 4 (4.8%). No case of severe depression was seen. Patients <25 years of age were the most affected. Depression was not significantly associated with age, gender, seizure type, or educational level.Conclusion:A significant proportion of Nigerian African epilepsy patients have depression, which may be easily overlooked, with far-reaching consequences on patients’ quality of life, morbidity, and mortality rates. There is need to regularly assess for and manage epilepsy-related depression in this population.

show abstract

Determination of prevalence of depression in an epilepsy clinic using a brief DSM-IV-based self-report questionnaire

Cited by 42 publications

References 36 publications

Evaluation of depression risk in LGI1 mutation carriers

Evaluation of depression risk in LGI1 mutation carriers

Validation of the Patient Health Questionnaire-9 (PHQ-9) for depression screening in adults with epilepsy

Depression in patients with epilepsy: A study from Enugu, South East Nigeria

Contact Info

Product

Resources

About